A total of 246 NSCLC specimens were analyzed, revealing 143 EGFR-mutant cases with significantly higher expression of METTL3 and ALKBH5.
Higher levels of METTL3 and ALKBH5 are associated with EGFR mutations in non-small cell lung cancer (NSCLC).
Patients with high METTL3 expression have a median time of 25.0 months.
Patients with high ALKBH5 expression have a median progression-free survival time of 24.1 months.
High expression of METTL3 and ALKBH5 independently predicts poorer progression-free survival in EGFR-mutant NSCLC.
The median progression-free survival time is significantly lower at 20.1 months for patients with high simultaneous expression of both METTL3 and ALKBH5.
Simplified
IntroductionNon-small cell lung cancer (NSCLC), which accounts for >85% of all lung cancers, is the most common solid malignant tumor, with high morbidity and mortality worldwide. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment is widely used clinically because the epidermal growth factor receptor (EGFR) is the main driver gene of lung cancer; however, the development of drug resistance is inevitable. Epigenetic abnormalities can also lead to tyrosine kinase inhibitor (TKI) resistance. However, the relationship between N6-methyladenosine (m6A)-related proteins and EGFR mutations in NSCLC and their clinical significance remain unclear. In this retrospective study, the expression of m6A-related regulatory factors in patients with EGFR mutations were analyzed to investigate their relationship with clinicopathological features and prognoses.MethodsThe association between m6A-related regulatory factors and NSCLC was analyzed using data derived from The Cancer Genome Atlas, case collection, follow-up, immunohistochemistry, and scoring.ResultsA total of 246 NSCLC specimens were examined in this study. Among these, 143 EGFR-mutant cases exhibited significantly higher expression of METTL3 and ALKBH5 compared to EGFR-wildtype specimens. The median time of patients with high METTL3 expression (SI >6) was 25.0 months, and that of patients with high ALKBH5 expression (SI >6) was 24.1 months in EGFR-mutant cases. High METTL3 and ALKBH5 expression levels are independent risk factors for progression-free survival in patients with EGFR mutations. The median progression-free survival time of patients with EGFR mutations was 45.7 months in those with high expression of METTL3 or ALKBH5 alone, whereas it decreased to 20.1 months in those with high simultaneous expression of METTL3 and ALKBH5.ConclusionsMETTL3 and ALKBH5 were upregulated in NSCLC tissues with EGFR mutations and significantly correlated with poor prognoses. Thus, METTL3 and ALKBH5 may serve as prognostic biomarkers in EGFR-mutant NSCLC.
Key numbers
25.0 months
Median with High METTL3 Expression
Patients with high METTL3 expression in EGFR-mutant NSCLC
24.1 months
Median with High ALKBH5 Expression
Patients with high ALKBH5 expression in EGFR-mutant NSCLC
20.1 months
Median with High METTL3 and ALKBH5 Expression
Patients with high expression of both METTL3 and ALKBH5
Full Text
We can’t show the full text here under this license.
Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
